Main Sector
Biotech Subsector
Medtech Subsector
Diagnostics Subsector
Indication
Biotech Phase of Development
Medtech/Diagnostics Phase of Development
Index
Countries
Reset

Dr. Ken YC Chow Hong Kong SAR China

As one of the top universities in Asia-Pacific, The Chinese University of Hong Kong (CUHK) is committed to knowledge transfer and seeks to foster partnerships to commercialise our university’s technologies in the best way to benefit both industry and society. In this regard, CUHK is continuously looking for potential partners/licensees in our below areas of biomedical technologies:

 

(1)   Therapeutics: Digestive Cancer / Diabetes / Liver Cancer / Neurological Disorders / Orthopaedic and Traumatological Disorders / Pluripotent Stem Cells (see https://goo.gl/Ozm5Gz)

(2)   Diagnostics: Cardiovascular Disorders / Digestive Cancers / Diabetes & its Comorbidities / Gynecology and Obstetrics / Orthopaedic & Traumatological Disorders / Wearables (see https://goo.gl/gcbdLF)

(3) Robotics: Surgical Robots / Endoscopes for Minimally Invasive Surgery and Diagnostic Purposes (see https://goo.gl/TrQSrz) 

Website:
http://cuhk-orkts.technologypublisher.com/site/inventions
Main Sector
Biotech Subsector
Medtech Subsector
Diagnostics Subsector
Indication
Biotech Phase of Development
Medtech/Diagnostics Phase of Development
Year Founded
1963
Dr. Ken YC Chow
Chinese University of Hong Kong
Technology Liaison Officer 
BIO

Prof. Edwin CHAN from the School Life Sciences from the Chinese University of Hong Kong is working on rare neurodegenerative diseases including the Huntington’s Disease (HD). He recently developed a new inhibitor for the treatment of HD. This patented technology is known as P3. P3 is a 13-amino acid peptidylic inhibitor that can potently suppress expanded Polyglutamine (PolyQ) / CAG RNA-induced nucleolar stress, and rescue neurodegeneration in animal disease model and cell death in patient fibroblasts.

 

The core benefits of this technology are:

(1)   the inhibitor is capable of directly interacting with and neutralizing the toxic expanded PolyQ / CAG RNA,

(2)   the mechanism of this inhibitor is well-defined that it reduces cellular p53 level and suppresses caspase activities, and

(3)   with proven potential to treat other polyglutamine diseases, such as spinocerebellar ataxias (SCA).

 

Related patent and references:

(1)   Zhang et al, Dis. Model. Mech, 2016 (http://www.ncbi.nlm.nih.gov/pubmed/26839389)

(2)   Tsoi et al, PNAS, 2012 (http://www.ncbi.nlm.nih.gov/pubmed/22847428)

(3)   US9,297,798 (http://www.google.com/patents/US9297798)

(4)   US Provisional patent (Priority date: 23 Dec 2015)

(5)   US non-Provisional patent (Priority date: 17 Feb 2016)

 

More details:

(1)   Introduction Slides: http://goo.gl/RSZf7g

(2)   Introduction Brochure: http://goo.gl/IdbVRG

(3)  Introduction Videos: https://goo.gl/nfZAbK